Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
CLEVELAND , Jan. 7, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018 . The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2018
Toggle Summary ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer
Study to Explore Clinical Benefits of Precise, High Dose Radiation Therapy Enabled by MRIdian's MR-guidance Combined with Daily On-table Adaptation in Pancreatic Cancer CLEVELAND , Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the enrollment of the first patient in the
Toggle Summary ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference
CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . Scott Drake , President and CEO, is scheduled to present at 8:30 a.m.
Toggle Summary Rob Fuchs joins ViewRay as Chief Human Resources Officer
CLEVELAND , Nov. 21, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs as Chief Human Resources Officer effective October 22 , 2018.  Mr.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.
Featured Items

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select